Zanubrutinib vs FCR in Fit Treatment-Naive Patients with Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison

被引：0
|
作者：
Munir, Talha [1 ]
Mohseninejad, Leyla [2 ]
Xu, Sheng [3 ]
Jevdjevic, Milica [4 ]
Bouwmeester, Walter [4 ]
Yang, Keri [5 ]
机构：
[1] St James Univ Hosp, Dept Haematol, Leeds, W Yorkshire, England
[2] BeiGene Netherlands BV, Schiphol, Netherlands
[3] BeiGene Shanghai Co Ltd, Shanghai, Peoples R China
[4] PRECISIONheor, London, England
[5] BeiGene USA, San Mateo, CA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-173172
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A Matching-Adjusted Indirect Comparison of Acalabrutinib with and without Obinutuzumab Versus Zanubrutinib in Treatment-Naive Chronic Lymphocytic Leukemia
    Allan, John N.
    Kittai, Adam S.
    James, Dan
    Ridge, Helen
    Miranda, Miguel
    Yong, Alan
    Fam, Fady
    Roos, Jack
    Shetty, Vikram
    Davids, Matthew S.
    Skarbnik, Alan
    BLOOD, 2023, 142
  • [2] A matching-adjusted indirect comparison of ELEVATE-TN versus SEQUOIA: acalabrutinib with and without obinutuzumab versus zanubrutinib in treatment-naive chronic lymphocytic leukemia
    Kittai, Adam
    Allan, John
    James, Dan
    Bridge, Helen
    Miranda, Miguel
    Yong, Alan
    Fam, Fady
    Roos, Jack
    Shetty, Vikram
    Skarbnik, Alan
    Davids, Matthew
    LEUKEMIA & LYMPHOMA, 2023, 64 : S82 - S83
  • [3] Matching-adjusted indirect comparisons of efficacy and safety of Acalabrutinib versus Ibrutinib in treatment-naive chronic lymphocytic leukemia
    Dietrich, S.
    Davids, M.
    Telford, C.
    Abhyankar, S.
    Waweru, C.
    Ringshausen, I.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 72 - 72
  • [4] Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naive chronic lymphocytic leukemia
    Davids, Matthew S.
    Telford, Claire
    Abhyankar, Sarang
    Waweru, Catherine
    Ringshausen, Ingo
    LEUKEMIA & LYMPHOMA, 2021, 62 (10) : 2342 - 2351
  • [5] Matching-Adjusted Indirect Treatment Comparison (MAIC) of Acalabrutinib Alone or in Combination with Obinutuzumab Versus Ibrutinib or Venetoclax Plus Obinutuzumab in Patients with Treatment-Naive Chronic Lymphocytic Leukemia
    Davids, Matthew S.
    Emeribe, Ugochinyere
    Gaitonde, Priyanka
    Cai, Ling
    BLOOD, 2021, 138
  • [6] Zanubrutinib, a promising treatment option for treatment-naive patients with chronic lymphocytic leukemia
    Stocker, Nicolas
    HEMATOLOGIE, 2022, 28 (05): : 207 - 207
  • [7] Adjusted indirect comparison of zanubrutinib and ibrutinib in first-line treatment of chronic lymphocytic leukemia
    Salmeron-Navas, Francisco Javier
    Barreiro-Fernandez, Ester Maria
    Fenix-Caballero, Silvia
    FARMACIA HOSPITALARIA, 2024, 48 (01) : 9 - 15
  • [8] Zanubrutinib monotherapy for patients with treatment-naive chronic lymphocytic leukemia and 17p deletion
    Tam, Constantine S.
    Robak, Tadeusz
    Ghia, Paolo
    Kahl, Brad S.
    Walker, Patricia
    Janowski, Wojciech
    Simpson, David
    Shadman, Mazyar
    Ganly, Peter S.
    Laurenti, Luca
    Opat, Stephen
    Tani, Monica
    Ciepluch, Hanna
    Verner, Emma
    Simkovi, Martin
    Osterborg, Anders
    Trneny, Marek
    Tedeschi, Alessandra
    Paik, Jason C.
    Kuwahara, Sowmya B.
    Feng, Shibao
    Ramakrishnan, Vanitha
    Cohen, Aileen
    Huang, Jane
    Hillmen, Peter
    Brown, Jennifer R.
    HAEMATOLOGICA, 2021, 106 (09) : 2354 - 2363
  • [9] A matching-adjusted indirect comparison (MAIC) of the efficacy and safety of acalabrutinib (acala) versus zanubrutinib (zanu) in relapsed or refractory chronic lymphocytic leukemia (RR CLL)
    Staber, P.
    Kittai, A.
    Skarbnik, A.
    Miranda, M.
    Yong, A. S.
    Roos, J.
    Hettle, R.
    Palazuelos-Munoz, S.
    Shetty, V.
    Ghia, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 218 - 218
  • [10] A matching-adjusted indirect comparison (MAIC) of the efficacy and safety of acalabrutinib (acala) versus zanubrutinib (zanu) in relapsed or refractory chronic lymphocytic leukemia (RR CLL)
    Kittai, Adam
    Skarbnik, Alan
    Miranda, Miguel
    Yong, Alan S. M.
    Roos, Jack
    Hettle, Robert
    Palazuelos-Munoz, Sarah
    Shetty, Vikram
    Ghia, Paolo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345